| Name | Title | Contact Details |
|---|
Impact Advisors is a nationally recognized healthcare consulting firm that is solving some of the toughest challenges in the industry by delivering strategic advisory, implementation and optimization services. Our comprehensive suite of patient access, clinical and revenue cycle services span the lifecycle of our clients` needs. Our experienced team has a powerful combination of clinical, revenue, operations, consulting, and IT experience. The firm has earned a number of prestigious industry and workplace awards including Best in KLAS® for thirteen consecutive years, Healthcare Informatics HCI 100, Crain`s Chicago Business Fast Fifty, as well as multi-year “best place to work” awards from: Modern Healthcare, Consulting Magazine, Becker`s Hospital Review and Achievers.
St. Josephs Hospital Buckhannon is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Buckhannon, WV. To find more information about St. Josephs Hospital Buckhannon, please visit www.stj.net
OneLegacy is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A patient-centric continuum of care will exist in the Greater Houston area that enhances overall population health, reduces health and wellness costs, connects all healthcare and wellness services providers and clients, facilitates region-wide healthcare and wellness policies and programs, and advances opportunities for long-term research for disease prevention and cures and evidence-based clinical protocols for optimal care.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.